Skip to main content

Table 2 5-year Overall Survival and Disease-Specific Survival by Anatomic and Prognosis Stage of TNBCs included in SEER cohort (N = 31,941)

From: AJCC 8th edition prognostic staging provides no better discriminatory ability in prognosis than anatomical staging in triple negative breast cancer

 StageNo. at risk5-year OS (95% CI)p-valueNo. at risk5-year DSS (95% CI)p-value
ASI12,70087.2(86.2,88.0)< 0.001**12,70093.5(82.8,94.2)< 0.001**
 IA12,29387.4(86.5,88.3)0.004*12,29393.8(93.1,94.4)0.001*
 IB40780.4(73.9,85.5) 40786.2(80.6,90.2) 
II14,29275.3(74.2,76.4)< 0.001#14,29282.7(81.8,83.7)< 0.001#
 IIA971378.5(77.2,79.7) 971386.0(84.9,87.0) 
 IIB457968.3(66.1,70.4) 457975.5(73.5,77.4) 
III494946.8(44.8,48.7)< 0.001494954.0(52.0,56.0)< 0.001
 IIIA251557.1(54.3,59.7) 251563.6(60.8,66.2) 
 IIIB116438.5(34.5,42.5) 116447.0(42.6,51.2) 
 IIIC127034.3(30.5,38.2) 127041.4(37.3,45.2) 
PSI12,29387.4(86.5,88.3)< 0.001**12,29393.8(93.1,94.4)< 0.001**
 IA40789.4(83.6,93.2)0.212*40794.6(89.2,97.3)0.259*
 IB11,88687.4(86.5,88.3) 11,88693.8(93.1,94.4) 
II10,72677.9(76.7,79.1)< 0.001#10,72685.5(84.4,86.5)< 0.001#
 IIA10,12078.6(77.3,79.8) 10,12086.0(85.0,87.0) 
 IIB60667.4(61.2,72.9) 60675.4(69.3,80.4) 
III892256.3(54.8,57.8)< 0.001892263.5(62.0,65.0)< 0.001
 IIIA398668.7(66.4,70.8) 398675.6(73.4,77.6) 
 IIIB36556.3(47.8,64.0) 36562.1(53.0,70.0) 
 IIIC457145.9(43.9,48.0) 457153.3(51.2,55.4) 
  1. **Log-rank test comparing proportions among all stage;*Log-rank test comparing proportions among Stage I; #Log-rank test comparing proportions among Stage II; Log-rank test comparing proportions among Stage III
  2. TNBC triple negative breast cancer, AS anatomic stage, PS prognosis stage, OS overall survival, DSS disease specific survival, CI confidence interval